A study in which patients suffering from moderate-to-severe psoriasis are assigned by chance, with neither the patient nor the doctor knowing the identity of the treatment in a given patient, to either the investigational drug CF101 or a matching dummy tablet, and are observed for beneficial and side effects.
- Registry ID
- EUCTR2010-024196-83
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Can-Fite BioPharma, Ltd.
- Start date
- 2011-03-29
- Completion date
- 2015-02-03
- Last update
- 2026-08-16
Conditions
- Moderate-to-Severe Plaque Psoriasis
Summary
The primary objectives of this study are to:
-Evaluate the efficacy of oral CF101 when administered at 2 mg twice daily (BID) for 16 weeks, compared with placebo, in patients with moderate-to-severe plaque psoriasis; and
-Evaluate the safety of oral CF101 in this patient population
Locations
- , , Bulgarian Drug Agency
View on source registry